Evidence map›Paper›PMID 35110411›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2022

Complex decay dynamics of HIV virions, intact and defective proviruses, and 2LTR circles following initiation of antiretroviral therapy.

Jennifer A White, Francesco R Simonetti, Subul Beg, Natalie F McMyn, Weiwei Dai, Niklas Bachmann, Jun Lai, William C Ford, Christina Bunch, Joyce L Jones and 4 more

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. The HIV Reservoir and Immune Landscape Across the Life Course of Women: Implications for Cure Strategies.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Jennifer A WhiteDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Francesco R SimonettiDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.ORCID 0000-0002-4165-660X
Subul BegDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Natalie F McMynDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Weiwei DaiDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.ORCID 0000-0002-9215-065X
Niklas BachmannDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Jun LaiDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
William C FordDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Christina BunchDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Joyce L JonesDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Ruy M RibeiroDepartment of Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545.
Alan S PerelsonDepartment of Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545.ORCID 0000-0002-2455-0002
Janet D SilicianoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Robert F SilicianoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205; rsiliciano@jhmi.edu.ORCID 0000-0002-1764-1993
Johns Hopkins University · USLos Alamos National Laboratory · US

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination ImmunotherapyUM1AI164570 · NIAID · WISTAR INSTITUTE · PI Luis J Montaner, James L. Riley · 2021 to 2026
$34.7M
Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
I4C 2.0: Immunotherapy for CureUM1AI164556 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Dan H. Barouch, John W Mellors · 2021 to 2026
$28.0M
Modeling Viral and T Lymphocyte DynamicsR01OD011095 · OD · TRIAD NATIONAL SECURITY, LLC · PI PERELSON, ALAN S · 2012 to 2024
$5.0M
Immune System Modeling/HIVR01AI028433 · NIAID · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 1990 to 2021
$3.7M
Pharmacology and Molecular Sciences Training Program: Enhancing Inclusivity Through Universal Design for Learning in Graduate CoursesT32GM135083 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Caren L. Freel Meyers · 2020 to 2026
$3.3M
Modeling the HIV latent reservoir, latency reversal and immunotherapeutics for HIV cureR01AI152703 · NIAID · TRIAD NATIONAL SECURITY, LLC · PI KE, RUIAN · 2020 to 2024
$3.0M
High resolution profiling and computational modeling of influenza virus-immune dynamics during natural infectionU01AI186993 · NIAID · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Christopher Byron Brooke, Ruian Ke · 2025 to 2026
$2.7M
NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI028433NIAID NIH HHS R01 AI152703NIAID NIH HHS U01 AI186993NIAID NIH HHS UM1 AI164556NIAID NIH HHS UM1 AI164560NIAID NIH HHS UM1 AI164570NIGMS NIH HHS T32 GM135083NIH HHS R01 OD011095
6 · The paper itself

Abstract

In persons living with HIV-1 (PLWH) who start antiretroviral therapy (ART), plasma virus decays in a biphasic fashion to below the detection limit. The first phase reflects the short half-life (<1 d) of cells that produce most of the plasma virus. The second phase represents the slower turnover (

Indexed as

Anti-Retroviral AgentsCD4-Positive T-LymphocytesCells, CulturedDNA, ViralHIV-1HIV InfectionsHumansLongitudinal StudiesProvirusesViral LoadVirionVirus LatencyVirus ReplicationAnti-Retroviral AgentsDNA, Viral2LTR circlesHIVIPDAlatent reservoirviral dynamics

Identifiers

PMID35110411
PMCPMC8833145
OpenAlexW4210797680

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.